Torii submits NDA for molluscum contagiosum treatment therapy in Japan
TO-208, known as VP-102 in the US and marketed under the brand name YCANTH, contains cantharidin as its active ingredient. A Phase III clinical trial was conducted in
ProQR Therapeutics has expanded its partnership with the Rett Syndrome Research Trust (RSRT), receiving an additional $8.1m in funding to support the advancement of Rett Syndrome therapy, AX-2402 into clinical trials.
This move grants Theratechnologies the ‘rights’ to potentially introduce treatments for familial chylomicronaemia syndrome (FCS), hereditary angioedema (HAE), and severe hypertriglyceridemia (sHTG) within the Canadian market. Under the
The single-asset focused partnership leverages Tubulis’ platforms, Tubutecan and Alco5, to create an ADC with stability and reduced off-target toxicity, addressing present treatment challenges. Under the agreement terms,